The MIP1α-targeting A/B heterodimeric vaccine gave significantly better survival (∼70%) than did the non-targeting control (∼20%) and an antigen control that expressed a scFv from an irrelevant B cell lymphoma (0%). Here, CCL3 is linked to B-cell non-Hodgkin lymphoma.